Sarepta Therapeutics (SRPT +5.5%) gains after announcing a collaboration agreement with University College and the Dubowitz Neuromuscular Centre in London to further develop exon-skipping drug therapies for Duchenne muscular dystrophy.
From other sites
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs